R.I. Lopez

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D. Gelber et al. · The Lancet · 2007 · 1.5K citations

Medicine, Oncology, Breast Oncology +15

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles, David Cameron, Igor Bondarenko et al. · European Journal of Cancer · 2016 · 124 citations

Medicine, Oncology, Pharmacology +16

[A zinc sulfate and usnic acid preparation used as post-surgical adjuvant therapy in genital lesions by Human Papillomavirus].

P. Scirpa, Giovanni Scambia, Valeria Masciullo et al. · PubMed · 1999 · 36 citations

Medicine, Gynecology, Surgery +17

Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial

István Láng, R. Bell, Fan Feng et al. · Clinical Oncology · 2013 · 29 citations

Medicine, Immunology, Oncology +17